AbbVie Inc
Latest AbbVie Inc News and Updates
Company & Industry OverviewsJazz Pharmaceuticals Is Focused on Label Expansion of Defitelio
Defitelio could help Jazz Pharmaceuticals become a prominent player not only in the treatment but also in the prevention of post-HSCT complications. Company & Industry OverviewsJAZZ Is Focused on Increasing Market Adoption of Defitelio
Jazz Pharmaceuticals (JAZZ) expects quarterly variability in Defitelio sales as the drug targets hepatic veno-occlusive disease (or VOD), an ultra-rare condition. Company & Industry OverviewsHow Allergan’s International Segment Performed in 2Q17
Allergan’s (AGN) international business includes total revenues from the sales of branded products as well as aesthetics products outside the US markets. Company & Industry OverviewsInside Jazz’s Net Profit Margin Expectations for 2017
For 2Q17, Jazz Pharmaceuticals (JAZZ) reported revenues close to $394 million, which represented a YoY growth of ~3% and sequential growth ~5%. HealthcareWhat Does AbbVie’s Dividend Curve Look Like?
AbbVie (ABBV) recorded a 12.0% rise in net revenue for 2016, mainly driven by Humira and Imbruvica. Company & Industry OverviewsAn Update on AbbVie’s Clinical Pipeline in 2017
In December 2016, the European Commission granted Venclyxto conditional marketing approval for the treatment of CLL in the presence of 17p deletion or TP53 mutation. Company & Industry OverviewsUpadacitinib: Opportunity for AbbVie’s Long-Term Growth?
ABBVie anticipates upadacitinib to be commercialized by 2019. If approved, AbbVie’s upadacitinib will directly compete with Pfizer’s (PFE) Xeljanz. Company & Industry OverviewsImbruvica Could Significantly Drive AbbVie’s Revenue Growth
In 2Q17, AbbVie’s (ABBV) Imbruvica generated revenues of around $626.0 million, which reflected a ~43.0% rise YoY and a ~14.0% rise QoQ. MiscellaneousThe Top Dividend-Growing Healthcare and Industrials Stocks
The sector has seen the weakest growth in its top and bottom lines due to uncertainty in terms of sector reforms. Company & Industry OverviewsInside Vertex Pharmaceuticals’ Revenue Trend
In 2016, Vertex Pharmaceuticals (VRTX) reported revenues of around ~$1.7 billion, which reflected a whopping 65% YoY (year-over-year) growth. MiscellaneousHow Are the Defensive and Cyclical Sectors Performing?
If we compare the performances of the defensive sectors, we can see that their YTD performance and one-year performances have been reasonably uniform with the exception of the energy and telecom sectors. Company & Industry OverviewsThis Product Pipeline Brings Hope for AbbVie’s Future Growth
AbbVie (ABBV) has a focused immunology pipeline in order to address various dermatologic and gastrointestinal conditions. Company & Industry OverviewsWhy Lupron Could Continue to Generate Steady Revenue
In 2016, AbbVie’s (ABBV) Lupron generated revenue of $821 million, a slight fall of 0.6% year-over-year (or YoY). In 1Q17, Lupron reported revenue of ~$194 million. Company & Industry OverviewsJohnson & Johnson’s Business Segments in 1Q17
Johnson & Johnson’s business includes three segments: Pharmaceuticals, Consumer, and Medical Devices. Company & Industry OverviewsCosentyx Enjoys Solid Demand as Psoriasis Therapy in Europe
In 2016, Novartis’s (NVS) Cosentyx surpassed its closest competitor, Eli Lilly’s (LLY) Taltz, in number of total weekly prescriptions in the US market. Company & Industry OverviewsHow Merck Performed in 2016
Merck (MRK) reported growth of 1% to $39.8 billion in its 2016 revenues as compared to $39.5 billion in 2015. Company & Industry OverviewsAstraZeneca’s Lynparza Is Still a Leading PARP Inhibitor in 2016
On October 26, 2016, AstraZeneca (AZN) announced that Lynparza managed to demonstrate a superior clinical profile in the Phase 3 SOLO-2 trial. Company & Industry OverviewsThe Competitive Landscape for Enbrel
Amgen (AMGN) launched Enbrel in the US in 1998. It became a major success for Amgen in no time and recorded $5.4 billion sales in 2015. Company & Industry OverviewsLoss of Patent Protection to Drag Pfizer’s Top Line
With the loss of patent protection for its flagship drug, Lipitor, Pfizer’s revenue fell to $48.8 billion in 2015, compared to $67 billion in 2010. Company & Industry OverviewsAcute Myeloid Leukemia: Growth Opportuny for AbbVie’s Venclexta?
AbbVie’s (ABBV) Venclexta has been granted FDA breakthrough therapy designation as a first line therapy for patients with acute myeloid leukemia who are ineligible for high-dose chemotherapy. Company & Industry OverviewsAbbVie Plans to Launch Psoriasis Therapy Risankizumab in 2019
AbbVie (ABBV) has completed enrollment in its Phase 3 pivotal trials testing investigational therapy risankizumab as a treatment option for psoriasis. Company & Industry OverviewsPhase 3 Trials Show Elagolix’s Efficacy for Endometriosis Pain
AbbVie (ABBV) and Neurocrine Biosciences (NBIX) have completed two phase 3 trials to evaluate the efficacy and safety of Elagolix as a treatment option for reducing pain associated with endometriosis as compared to a placebo. Company & Industry OverviewsHow GILD Plans to Battle through Impending HIV Patent Cliff
Gilead Sciences (GILD) is the leading biotechnology player in the global HIV market. Company & Industry OverviewsPfizer’s Hospira Deal: Catching Up a Year Later
On September 13, 2015, Pfizer (PFE) completed its acquisition of Hospira for $17 billion. Company & Industry OverviewsWhy Pfizer’s Enbrel Faces a Sales Decline
Wall Street analysts expect Enbrel to earn $3 billion and $2.5 billion from the sale outside US and Canada in fiscal 2016 and 2017, respectively. Company & Industry OverviewsAbbVie Expects to Commercialize Selective JAK1 Inhibitor ABT-494
Currently being tested in six Phase 3 trials, ABT-494 is expected to be a significant improvement in the standard of care for rheumatoid arthritis. Company & Industry OverviewsHow AbbVie Expects Risankizumab to Be a Transformative Therapy
AbbVie (ABBV) expects its investigational drug Risankizumab to be a transformative therapy for psoriasis. Earnings ReportRegeneron’s Robust Pipeline
Regeneron’s (REGN) robust pipeline consists of 13 molecules in various phases of development. Sarilumab is under review with the FDA. Company & Industry OverviewsWhy Is AbbVie’s Valuation Multiple Rising in July?
AbbVie believes that the Market has misunderstood the growth potential of Rova-T, which is expected to earn $1.5 billion–$2 billion in peak sales even under extremely conservative assumptions. Company & Industry OverviewsWhy AbbVie Expects Rova-T to See Big Peak Sales
AbbVie project that Rova-T, a DLL3-targeted antibody conjugate acquired through the acquisition of Stemcentrx, will earn $5 billion in peak sales. Company & Industry OverviewsWhy AbbVie Continues to Explore Imbruvica for Diffuse Large B-Cell Lymphoma
AbbVie hopes to position Imbruvica as a therapy for multiple indications: follicular lymphoma, solid tumor, and diffuse large B-cell lymphoma, among others. Company & Industry OverviewsWhy AbbVie Expects PTK7 to Enhance Its Oncology Capabilities
Now in its phase-1 clinical trial, AbbVie’s PF-06647020, an ADC targeting protein kinase 7 could become a major therapy for advanced solid tumors. Company & Industry OverviewsUnderstanding Trinity: Inside the Testing of AbbVie’s Rova-T
Trinity is a phase-2 clinical trial that tests the use of Rova-T as a third-line therapy for SCLC (small cell lung cancer). Company & Industry OverviewsCan Stemcentrx’s Cancer Stem Cell Technology Really Accelerate Innovation for AbbVie?
The acquisition of Stemcentrx has added CSC (cancer stem cell) technology platform to AbbVie’s (ABBV) oncology portfolio. Company & Industry OverviewsVenclexta: The First BCL-2 Inhibitor Cancer Therapy to Be Approved by the FDA
On April 11, 2016, Venclexta became the first BCL-2 inhibitor therapy to be approved by the FDA for chronic lymphocytic leukemia patients with 17p deletion. Company & Industry OverviewsAn Inside Look at Incyte’s Product Portfolio
Incyte’s (INCY) product portfolio includes drugs for oncology as well as non-oncology. For oncology, its product portfolio includes targeted therapies as well as immunotherapies. Company & Industry OverviewsWill Elagolix Make Neurocrine Biosciences a Key Women’s Health Name?
If approved, Elagolix could present fierce competition for existing drugs like Teva Pharmaceuticals’ (TEVA) Aygestin and Astrazeneca’s (AZN) Zoladex. Company & Industry OverviewsBendeka: How Teva Plans to Safeguard Oncology Revenues
In the first quarter of 2016, Teva Pharmaceutical Industries (TEVA) launched a new drug, Bendeka, in partnership with Eagle Pharmaceuticals. Company & Industry OverviewsHow Baxter’s Biosciences Spin-off into Baxalta Improved Its Valuation
On July 1, 2015, Baxter separated its Biosciences division into a new entity named Baxalta in an effort to divest risky segments and streamline operations. Company & Industry OverviewsAbbVie’s Therapies in Virology, Neurology, and Women’s Health
In addition to its Oncology and Immunology segments, AbbVie is focused on launching innovative therapies in its Virology, Neurology, and Women’s Health segments. Company & Industry OverviewsDissecting Abbott Laboratories: A Key Business Model Analysis
Since 2013, Abbott Laboratories has generated revenues from a diversified healthcare business spanning across geographies and four primary segments. Earnings ReportAbbVie’s Net Profit Margin Expected to Reach 29.8% in 4Q15
AbbVie (ABBV) has continued to improve its operational efficiency, which is expected to result in a net profit margin of 29.8%, a YoY increase of 6.3%. In 3Q15, AbbVie realized a net proft margin of 30.4%. Earnings ReportRevlimid Continues to Drive Celgene’s Revenue
Revlimid (lenalidomide) is one of Celgene’s (CELG) main revenue drivers. It had revenues of $1.4 billion in 3Q15, excluding the adverse impact of foreign exchange fluctuations. Earnings ReportAbbVie’s Late-Stage Research Pipeline Could Boost Future Revenues
In partnership with Bristol-Myers Squibb, AbbVie is exploring elotuzumab to treat relapsed refractory multiple myeloma. The drug also received a breakthrough therapy designation from the FDA on May 19, 2014. Company & Industry OverviewsA Key Look at Abbott Laboratories’ Acquisitions and Divestments
Inorganic growth through acquisitions has led to the expansion of Abbott Laboratories across geographies and to the broadening of its product portfolio. Company & Industry OverviewsIntroducing Abbott Laboratories, a Leading Global Healthcare Company
Abbott Laboratories operates across more than 150 countries, employs over 73,000 people, and is the global leader in the nutrition subsector. MiscellaneousMerck Will Soon See a Decision on Its New Hepatitis C Therapy
The FDA has scheduled the Prescription Drug User Fee Act (or PDUFA) date for Merck’s new hepatitis C combination therapy for January 28, 2016. Earnings ReportCelgene Has a Strong Inflammation and Immunology Pipeline
In 3Q15, Celgene had a strong inflammation and immunology pipeline. The company witnessed the progress of its key investigational drug GED-0301. Earnings ReportBiogen’s Collaborative Arrangements See Strong Development in 3Q15
In 3Q15, Biogen saw several positive developments for the drugs developed under its various collaborative arrangements. Company & Industry OverviewsAlexion Pharmaceuticals Expands Soliris Labels
Alexion Pharmaceuticals is actively involved in expanding the approved labels for its flagship product Soliris.